Related Experiment Video
Updated: Oct 10, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Hepatitis C infection and chronic kidney disease among Hispanics/Latinos
Eugenia Wong1, Ana C Ricardo2, Sylvia E Rosas3
1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Insights
Hepatitis C virus (HCV) infection is not strongly linked to new chronic kidney disease (CKD) in Hispanics/Latinos. While HCV+ individuals showed faster eGFR decline, it did not translate to increased CKD incidence in this cohort.
Area of Science:
- Nephrology
- Infectious Diseases
- Epidemiology
Background:
- Hepatitis C virus (HCV) infection can lead to secondary kidney diseases.
- HCV is a potential risk factor for chronic kidney disease (CKD), but data in Hispanic/Latino populations is limited.
Purpose of the Study:
- To investigate the association between HCV infection and the incidence of CKD among Hispanics/Latinos.
- To analyze the impact of HCV on estimated glomerular filtration rate (eGFR) and albuminuria.
Main Methods:
- Prospective cohort study of 10,430 Hispanics/Latinos from the Hispanic Community Health Study/Study of Latinos.
- HCV+ defined by antibody and RNA/recombinant immunoblot assay testing.
- Incident CKD defined by eGFR <60 mL/min/1.73 m² or albuminuria thresholds; Poisson and linear regression used for analysis.
Main Results:
- Over 5.9 years, 712 incident CKD events occurred.
- HCV+ was not associated with incident CKD (IRR 1.29).
- HCV+ was associated with higher eGFR risk stages (IRR 2.39) and a faster annualized eGFR decline (-0.69 mL/min/m²/year).
Conclusions:
- This study found no strong evidence linking HCV infection to new-onset CKD in the Hispanic/Latino population.
- HCV infection may not significantly increase CKD risk in this demographic.
- Direct-acting antiviral treatment is recommended for all HCV+ individuals, irrespective of kidney disease status.
Abstract:
Viral infections, including hepatitis C, can cause secondary glomerular nephropathies. Studies suggest that hepatitis C virus infection (HCV+) is a risk factor for chronic kidney disease (CKD) but evidence of this relationship is lacking among Hispanics/Latinos. We examined the association between HCV+ and incident CKD in a prospective cohort of Hispanics/Latinos enrolled in the Hispanic Community Health Study/Study of Latinos. HCV+ was defined by detectable HCV antibodies with additional confirmation through HCV RNA or recombinant immunoblot assay testing. Incident CKD was defined by an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or sex-specific threshold for albuminuria measured during follow-up. We used Poisson regression to estimate incidence rate ratios (IRR) of CKD and changes in eGFR- or albuminuria-based risk stages, separately. We used linear regression to estimate associations with continuous, annualized changes in eGFR and albuminuria.Over a follow-up period of 5.9 years, 712 incident CKD events occurred among 10,430 participants. After adjustment for demographic characteristics and comorbidities, HCV+ was not associated with incident CKD, defined by eGFR and albuminuria thresholds (IRR 1.29, 95% Confidence Interval 0.61, 2.73). HCV+ was significantly associated with higher eGFR risk stages (IRR 2.39, 95% CI 1.47, 3.61) with most participants transitioning from stage G1 to G2. HCV+ was associated with a continuous, annualized eGFR decline of -0.69 mL/min/m2/year (95% CI -1.23, -0.16). This large, cohort study did not find evidence of a strong association between HCV+ and new-onset CKD among Hispanics/Latinos. HCV infection may not be associated with risk of CKD among Hispanics/Latinos, although treatment with direct-acting antivirals is recommended for all HCV+ individuals, including those with established CKD or end-stage kidney disease.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

